NEW YORK (GenomeWeb News) – UK biomarker discovery firm Abcodia announced today it has secured £1 million ($1.4 million) in funding.
The funding comes from Albion Ventures and UCL Business. Abcodia will use the investment to conduct translational studies using its longitudinal serum collection licensed from University College London.
Julie Barnes, CEO of the firm, which was founded in February, added that Abcodia will use the funding for additional hires and to build partnerships. The firm is focused on cancer, diabetes, osteoporosis, and rheumatoid arthritis biomarkers.